Valneva SE (VALN) Net Income towards Common Stockholders (2021 - 2026)

Valneva SE (VALN) reported Net Income towards Common Stockholders of -$27.7 million for Q1 2026, down 342.51% on a YoY basis from $11.4 million in Q1 2025, and up 52.41% sequentially from -$58.3 million in Q4 2025.

Valneva SE (VALN) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends

Valneva SE (VALN) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$27.7 million in Q1 2026.

  • For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 342.51% year-over-year to -$27.7 million; the trailing twelve-month figure through Mar 2026 stood at -$141.7 million (down 116.52% YoY), and the FY2025 full-year result was -$134.1 million, down 1029.61% from the prior year.
  • Net Income towards Common Stockholders grew to -$27.7 million in Q1 2026, from -$58.3 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $74.1 million in Q1 2024 to a low of -$2.1 billion in Q3 2022.
  • A 5-year average of -$151.1 million and a median of -$24.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Across the five-year window, Net Income towards Common Stockholders tumbled 1033.07% in 2022 and soared 516.53% in 2024, its largest moves.
  • Tracing VALN's Net Income towards Common Stockholders over 5 years: stood at -$57.5 million in 2022, then jumped by 53.39% to -$26.8 million in 2023, then gained by 16.72% to -$22.3 million in 2024, then tumbled by 161.21% to -$58.3 million in 2025, then soared by 52.41% to -$27.7 million in 2026.
  • Business Quant data shows VALN's Net Income towards Common Stockholders at -$27.7 million in Q1 2026, -$58.3 million in Q4 2025, and -$43.4 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -625.73
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -0.68
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 366.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -453.82 Mn
10 Valneva SE 811.46 Mn 688.23 Mn 5.08 Mn -27.74 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -27.74 Mn
Dec 31, 2025 -58.29 Mn
Sep 30, 2025 -43.39 Mn
Jun 30, 2025 -12.30 Mn
Mar 31, 2025 -6.27 Mn
Dec 31, 2024 -22.32 Mn
Sep 30, 2024 -13.67 Mn
Jun 30, 2024 -23.20 Mn
Mar 31, 2024 74.10 Mn
Dec 31, 2023 -26.80 Mn
Sep 30, 2023 -24.18 Mn
Jun 30, 2023 -20.03 Mn
Mar 31, 2023 -17.79 Mn
Dec 31, 2022 -57.49 Mn
Sep 30, 2022 -2.11 Bn
Jun 30, 2022 -156.31 Mn
Mar 31, 2022 -28.10 Mn
Dec 31, 2021 193.58 Mn
Sep 30, 2021 -185.83 Mn
Jun 30, 2021 -68.19 Mn